Publicacions (138) Publicacions de Javier Del Pino Montes

2023

  1. Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial

    Journal of Bone and Mineral Research, Vol. 38, Núm. 4, pp. 471-479

  2. Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536

2022

  1. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 14, Núm. 1, pp. 5-12

  2. Reply to Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women

    Journal of Bone and Mineral Research

2021

  1. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

    Journal of Bone and Mineral Research, Vol. 36, Núm. 10, pp. 1967-1978

  2. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

2020

  1. A mutation in p62 protein (p. R321C), associated to Paget's disease of bone, causes a blockade of autophagy and an activation of NF-kB pathway

    Bone, Vol. 133

  2. Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort

    Journal of Bone and Mineral Research, Vol. 35, Núm. 7, pp. 1246-1252

  3. The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey

    Rheumatology International, Vol. 40, Núm. 2, pp. 303-311

2019

  1. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study

    Rheumatology International, Vol. 39, Núm. 12, pp. 2015-2024

  2. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  3. Objectives and methodology of BIOBADASER phase III

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236

  4. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

  5. SER recommendations on the use of biological drugs in primary Sjögren's syndrome

    Reumatologia Clinica, Vol. 15, Núm. 6, pp. 315-326

  6. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment

    Endocrine, Vol. 64, Núm. 3, pp. 441-455

  7. Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone

    BMJ Open, Vol. 9, Núm. 9

2018

  1. Complex regional pain syndrome

    Medicine (Spain), Vol. 12, Núm. 60, pp. 3524-3532

  2. Diagnostic and treatment protocol of osteomalacia

    Medicine (Spain), Vol. 12, Núm. 60, pp. 3542-3546

  3. Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density

    Annals of the rheumatic diseases, Vol. 77, Núm. 3, pp. 378-385

  4. Polymorphisms in genes implicated in base excision repair (BER) pathway are associated with susceptibility to Paget's disease of bone

    Bone, Vol. 112, pp. 19-23